Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?


Deniz S., UYSAL T. K. , Capasso C., Supuran C. T. , ÖZENSOY GÜLER Ö.

Journal of Enzyme Inhibition and Medicinal Chemistry, vol.36, no.1, pp.1230-1235, 2021 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 36 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.1080/14756366.2021.1924165
  • Title of Journal : Journal of Enzyme Inhibition and Medicinal Chemistry
  • Page Numbers: pp.1230-1235

Abstract

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.The ongoing Covid-19 is a contagious disease, and it is characterised by different symptoms such as fever, cough, and shortness of breath. Rising concerns about Covid-19 have severely affected the healthcare system in all countries as the Covid-19 outbreak has developed at a rapid rate all around the globe. Intriguing, a clinically used drug, acetazolamide (a specific inhibitor of carbonic anhydrase, CA, EC 4.2.1.1), is used to treat high-altitude pulmonary oedema (HAPE), showing a high degree of clinical similarities with the pulmonary disease caused by Covid-19. In this context, this preliminary study aims to provide insights into some factors affecting the Covid-19 patients, such as hypoxaemia, hypoxia as well as the blood CA activity. We hypothesise that patients with Covid-19 problems could show a dysregulated acid–base status influenced by CA activity. These preliminary results suggest that the use of CA inhibitors as a pharmacological treatment for Covid-19 may be beneficial.